Brokerages Set Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) PT at $11.00

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) have been given a consensus recommendation of “Hold” by the five ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $11.00.

Several research analysts recently weighed in on NBTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research report on Wednesday, October 8th. Leerink Partners reaffirmed an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a research note on Tuesday, November 4th. Finally, Wall Street Zen upgraded shares of Nanobiotix to a “hold” rating in a research report on Saturday, October 25th.

Hedge Funds Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. purchased a new position in shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 5,356 shares of the company’s stock, valued at approximately $101,000. Institutional investors own 38.81% of the company’s stock.

Nanobiotix Trading Down 0.9%

NASDAQ NBTX opened at $20.99 on Wednesday. The stock has a 50-day simple moving average of $21.57 and a two-hundred day simple moving average of $15.79. Nanobiotix has a fifty-two week low of $2.95 and a fifty-two week high of $30.35.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.